These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 10225963)

  • 41. The CD28/CTLA-4:B7 receptor system in experimental autoimmune encephalomyelitis.
    Linsley PS
    J Clin Invest; 1995 Jun; 95(6):2429-30. PubMed ID: 7539451
    [No Abstract]   [Full Text] [Related]  

  • 42. Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice.
    Freeman GJ; Borriello F; Hodes RJ; Reiser H; Hathcock KS; Laszlo G; McKnight AJ; Kim J; Du L; Lombard DB
    Science; 1993 Nov; 262(5135):907-9. PubMed ID: 7694362
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Perioperative administration of FTY720 and CTLA4IG in rat heart transplantation.
    Ohba M; Li XK; Kita Y; Tamura A; Enosawa S; Sasakuri S; Ogoshi S; Amemiya H; Suzuki S
    Transplant Proc; 2000 Nov; 32(7):2024-5. PubMed ID: 11120049
    [No Abstract]   [Full Text] [Related]  

  • 44. CD28/CTLA-4 receptor structure, binding stoichiometry and aggregation during T-cell activation.
    Linsley PS; Ledbetter J; Peach R; Bajorath J
    Res Immunol; 1995; 146(3):130-40. PubMed ID: 8525042
    [No Abstract]   [Full Text] [Related]  

  • 45. Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation.
    Vandenborre K; Van Gool SW; Kasran A; Ceuppens JL; Boogaerts MA; Vandenberghe P
    Immunology; 1999 Nov; 98(3):413-21. PubMed ID: 10583602
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reversal of CTLA4Ig-mediated tolerance to cardiac allografts by exogenous interleukin-2.
    Arima T; Rehman A; Flye MW
    Transplant Proc; 1997; 29(1-2):1305-6. PubMed ID: 9123318
    [No Abstract]   [Full Text] [Related]  

  • 47. CTLA-4 upregulation during aging.
    Leng Q; Bentwich Z; Borkow G
    Mech Ageing Dev; 2002 Jul; 123(10):1419-21. PubMed ID: 12297345
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New molecules on dendritic cells and their interactions with T lymphocytes.
    Hart DN; Starling GC; Egner W; Hock BD; McLellan AD; McKenzie JL; Williams LA; Simmons DL
    Adv Exp Med Biol; 1995; 378():351-4. PubMed ID: 8526091
    [No Abstract]   [Full Text] [Related]  

  • 49. More negative feedback?
    Coyle AJ; Gutierrez-Ramos JC
    Nat Immunol; 2003 Jul; 4(7):647-8. PubMed ID: 12830142
    [No Abstract]   [Full Text] [Related]  

  • 50. CTLA-4 and T cell activation.
    Oosterwegel MA; Greenwald RJ; Mandelbrot DA; Lorsbach RB; Sharpe AH
    Curr Opin Immunol; 1999 Jun; 11(3):294-300. PubMed ID: 10375557
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of peripheral clonal deletion in tolerance induction with bone marrow transplantation and costimulatory blockade.
    Wekerle T; Sayegh MH; Chandraker A; Swenson KG; Zhao Y; Sykes M
    Transplant Proc; 1999; 31(1-2):680. PubMed ID: 10083292
    [No Abstract]   [Full Text] [Related]  

  • 52. T-cell stimulation: an abundance of B7s.
    Abbas AK; Sharpe AH
    Nat Med; 1999 Dec; 5(12):1345-6. PubMed ID: 10581066
    [No Abstract]   [Full Text] [Related]  

  • 53. Acute graft-versus-host disease without costimulation via CD28.
    Speiser DE; Bachmann MF; Shahinian A; Mak TW; Ohashi PS
    Transplantation; 1997 Apr; 63(7):1042-4. PubMed ID: 9112366
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Feasibility of immunosuppression in composite tissue allografts by systemic administration of CTLA4Ig.
    Iwasaki N; Gohda T; Yoshioka C; Murakami M; Inobe M; Minami A; Uede T
    Transplantation; 2002 Feb; 73(3):334-40. PubMed ID: 11884927
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effect of CD28/B7 blockade on alloreactive T and B cells after liver cell transplantation.
    Reddy B; Gupta S; Chuzhin Y; Kalergis AM; Budhai L; Zhang M; Droguett G; Horwitz MS; Chowdhury JR; Nathenson SG; Davidson A
    Transplantation; 2001 Mar; 71(6):801-11. PubMed ID: 11330546
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The CD28 and CTLA-4 receptor family.
    June CH; Vandenberghe P; Thompson CB
    Chem Immunol; 1994; 59():62-90. PubMed ID: 7945930
    [No Abstract]   [Full Text] [Related]  

  • 57. The emerging role of CTLA-4 as an immune attenuator.
    Thompson CB; Allison JP
    Immunity; 1997 Oct; 7(4):445-50. PubMed ID: 9354465
    [No Abstract]   [Full Text] [Related]  

  • 58. Tolerating differences.
    Sikorski R; Peters R
    Science; 1999 Jul; 285(5426):357-8. PubMed ID: 10438301
    [No Abstract]   [Full Text] [Related]  

  • 59. The B7/CD28/CTLA4 T-cell activation pathway. Implications for inflammatory lung disease.
    Green JM
    Am J Respir Cell Mol Biol; 2000 Mar; 22(3):261-4. PubMed ID: 10696061
    [No Abstract]   [Full Text] [Related]  

  • 60. The complexities of T-cell co-stimulation: CD28 and beyond.
    Sperling AI; Bluestone JA
    Immunol Rev; 1996 Oct; 153():155-82. PubMed ID: 9010723
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.